- UnitedHealth Group's stock experienced a steep decline, despite beating earnings estimates.
- The rising medical care ratio highlights growing medical costs.
- Analysts maintain a positive outlook, suggesting potential recovery.
UnitedHealth Group (UNH) witnessed a dramatic 9% drop in its share price at the market open, the sharpest decline since June 2023. The unexpected slide followed the release of its third-quarter earnings report, which despite surpassing analysts' expectations, raised concerns over escalating medical costs.
The health insurance giant, with a formidable market cap of $531.88 billion, reported adjusted earnings per share (EPS) of $7.15, surpassing the consensus estimate of $7.06. Revenue climbed by 9.2% year-over-year, reaching $100.8 billion and outpacing the anticipated $99.2 billion. However, the medical care ratio, a critical measure of medical costs, rose to 85.2% from 82.3% last year, signaling increased expenses that unsettled investors.
While UnitedHealth's stock has enjoyed a decade-long upward trajectory, largely propelled by its Optum segment, the rise in medical care costs poses a significant challenge. The broader implications for the healthcare sector remain uncertain, but this development could signal a trend of rising costs industry-wide.
Industry analysts remain optimistic about the company's prospects, with a consensus Strong Buy rating and an average price target of $625.39, indicating a potential upside of 3.3%. Despite the current volatility, experts predict that UnitedHealth will maintain its 2024 outlook, projecting adjusted EPS between $27.50 and $27.75.
Efforts to contact UnitedHealth for comments went unanswered. Without a strategic approach to managing escalating costs, the company might face further scrutiny from investors and analysts alike.
This story will be updated as more information becomes available.